Trovagene Bets on Digital PCR as Detection Technology for Urine-Based MDx Testing Platform | GenomeWeb

This article has been updated from a previous version to include information about the current status of Fluidigm's collaboration with Novartis.

Trovagene, a San Diego-based company that has spent several years attempting to commercialize molecular diagnostic tests based on detecting cell-free nucleic acids in urine, may have finally found its ideal detection technology: digital PCR.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.